BenzingaT3·5mo ago
SHPH Shuttle Pharmaceuticals Holdings, Inc. Common Stock
XNAS
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
SHPH
—
—
Key stats
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $0.0B
- Employees
- 2
- List Date
- 2022-08-31
- CIK
- 0001757499
- Next Earnings
- 2026-11-12
- Headquarters
- Gaithersburg, MD
- Homepage
- https://www.shuttlepharma.com
Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company has one operating segment with a focus on the development of novel drug therapies, including cancer therapies, extending new applications of radiation therapy, and other drug development, including through the use of the Molecule.ai platform by the company as well as licensing the right to use Molecuile.ai to others. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy,…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|
| Jan | -- | 3.33% | -22.62% | -11.52% | 11.60% | -4.80% |
| Feb | -- | -7.39% | 0.38% | -15.44% | -44.13% | -16.64% |
| Mar | -- | -28.88% | 6.76% | -29.29% | -28.55% | -19.99% |
| Apr | -- | 21.32% | -3.14% | -34.41% | 53.16% | 9.23% |
| May | -- | -21.23% | 23.49% | -37.84% | -24.10% | -14.92% |
| Jun | -- | 3.60% | -25.69% | -13.10% | -39.02% | -18.55% |
| Jul | -- | -25.61% | 0.05% | -15.90% | 11.11% | -7.59% |
| Aug | 0.00% | -18.69% | -34.73% | -5.71% | -0.30% | -11.89% |
| Sep | -91.24% | -21.21% | -38.83% | 5.03% | 11.91% | -26.87% |
| Oct | -32.99% | -18.75% | 54.55% | -21.84% | 27.72%* | 1.74% |
| Nov | -40.33% | 4.15% | -49.22% | -53.87% | -- | -34.82% |
| Dec | 34.25% | -9.02% | 5.53% | 7.78% | -- | 9.63% |
| Total | -95.30% | -75.28% | -75.62% | -93.93% | -50.00% | -78.02% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $4.76
SMA 50: $4.07
SMA 200: $7.27
Current: $5.04
EMA 12: $4.87
EMA 26: $4.61
MACD: 0.2663 | Signal: -0.0507
BULLISH
ADX (14): 39.11
TREND
+DI: 20.39
−DI: 31.65
Momentum Oscillators
RSI (14): 57.42
NEUTRAL
Stoch %K: 57.65
Stoch %D: 51.77
Williams %R: -28.78
Volume & Volatility
BB Upper: $5.86
BB Lower: $3.66
NEUTRAL
OBV: 127,744,827
Vol SMA 20: 45,403
Vol ROC: -27.83%
ATR: $0.48
True Range: $0.33
HV 20: 106.6%
HV 30: 107.7%
HV 60: 108.9%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis
LLM Stock Analysis Report: SHPH
Executive Summary
Overall Assessment: NEUTRAL (Confidence Level: 6/10)
Key Drivers:
- Bullish MACD signal
- Recent positive news sentiment
- Trend direction: Short-term uptrend, Medium-term sideways movement, Long-term downtrend
Primary Risks:
- High risk of mean reversion due to recent price increase
- Potential for technical correction if RSI crosses above 70
Investment Thesis: SHPH presents a mixed picture with both bullish and bearish signals. The company's recent news headlines are overwhelmingly positive, but the stock's long-term trend is downward. A neutral stance is recommended, as there are valid arguments on both sides.
Recent News Sentiment Impact: The positive news sentiment has contributed to the short-term uptrend, but it may not be sustainable in the long term.
Technical Analysis
Trend Direction:
- Short-term (1-4 weeks): Uptrend
- Medium-term (1-3 months): Sideways movement
- Long-term (3-12 months): Downtrend
Support/Resistance Levels:
- SMA 20: $3.95
- SMA 50: $3.59
- Upper Bollinger Band: $4.67
Momentum Signals:
- RSI (14): 49.20 (neutral)
- MACD: -0.01 / Signal: -0.04 / Histogram: 0.03 (bullish)
Volume Analysis:
- Volume SMA 20: 149234.91
- On-Balance Volume (OBV): 126908102.17
- Volume Rate of Change: -71.00%
News & Sentiment Analysis
Recent Headlines Summary: The recent news headlines are overwhelmingly positive, highlighting the company's successful mergers and acquisitions.
Sentiment Assessment: Positive sentiment dominates, with an aggregate sentiment score of 8/10.
Catalyst Identification: No upcoming events or catalysts identified.
Market Narrative: The positive news sentiment aligns with the short-term uptrend, but it may not be sustainable in the long term.
Risk & Volatility Assessment
Beta Interpretation: Beta is relatively low at 0.73 compared to SPY, indicating lower volatility.
Volatility Regime: Current volatility is high, with a Historical Volatility score of HV20 128.0% / HV30 132.0% / HV60 155.6%.
Options Market Signals: No options data available.
Downside Protection: The recent price increase has pushed the stock above its upper Bollinger Band, making it susceptible to mean reversion.
Market Context & Positioning
Sector Performance: SHPH's sector (Healthcare) is performing well overall, with a relative strength index score of 60/100.
Institutional Activity: No notable institutional activity observed.
Correlation Analysis: The stock has a low correlation coefficient of 0.07 compared to the SPY, indicating limited market influence.
Relative Valuation: SHPH's current price is within its historical trading range.
Key Levels & Action Items
Critical Price Levels:
- SMA 20: $3.95
- Upper Bollinger Band: $4.67
Breakout/Breakdown Levels:
- Mean reversion potential if RSI crosses above 70
Time-Sensitive Catalysts: No upcoming events or catalysts identified.
Risk Management: A stop-loss level of $3.30 is recommended, with a position sizing consideration to limit exposure.
Please note that this analysis is based on the provided data and should not be considered personalized investment advice.
Generated
News
All SHPH news →
BenzingaT3·12mo ago
BenzingaT3·19mo ago
GlobeNewswire Inc.T3·23mo ago
BenzingaT3·24mo ago
GlobeNewswire Inc.T3·24mo ago
GlobeNewswire Inc.T3·25mo ago
Investing.comT3·27mo ago
GlobeNewswire Inc.T3·27mo ago
GlobeNewswire Inc.T3·28mo ago
Showing 1–10 of 50
Page 1 of 5
SHPH Options Activity & IV Rank
Loading options activity...
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
30 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Risk Metrics
Beta: 0.7061
Alpha: -90.36%
Correlation: 0.0636
R-Squared: 0.4%
Stock Volatility: 141.5%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Low volatility - stock moves less than market
Beta & Alpha Over Time
Notable investors who own SHPH
1 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Citadel Hedge fund Ken Griffin | $79K | #5873 of 6285 | new | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
SHPH Institutional Ownership (13F)
Latest filings — 2026-06-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
SHPH Insider Trading (Form 4)
Latest: 2026-07-15Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-07-15 | HRT FINANCIAL LP | 10%+ Owner | Sell (S) | −83,149 | $4.48 | -$372.7K | EDGAR |
| 2026-07-13 | HRT FINANCIAL LP | 10%+ Owner | Buy (P) | +8,997 | $3.36 | $30.2K | EDGAR |
| 2026-07-09 | HRT FINANCIAL LP | 10%+ Owner | Sell (S) | −29,111 | $3.45 | -$100.5K | EDGAR |
| 2026-07-07 | HRT FINANCIAL LP | 10%+ Owner | Mixed | −1,171 | $3.52 | -$3.9K | EDGAR |
| 2026-07-02 | HRT FINANCIAL LP | 10%+ Owner | Buy (P) | +3,959 | $3.30 | $13.1K | EDGAR |
| 2026-07-01 | HRT FINANCIAL LP | 10%+ Owner | Buy (P) | +32,591 | $3.40 | $110.7K | EDGAR |
| 2025-08-13 | Steven M Richards | Director | Grant (A) | +29,240 RSU | — | EDGAR | |
| 2025-08-12 | George Scorsis | Director | Grant (A) | +29,240 RSU | — | EDGAR | |
| 2025-08-12 | Joseph Tung | Director | Grant (A) | +29,240 RSU | — | EDGAR | |
| 2025-08-12 | Timothy J. Lorber | Chief Financial Officer | Grant (A) | +54,094 RSU | — | EDGAR | |
| 2025-08-12 | Oleh Nabyt | Director | Grant (A) | +29,240 RSU | — | EDGAR | |
| 2024-10-09 | Mira Jung | Chief Scientific Officer | Award (A) | −598 | $11.28 | -$6.7K | EDGAR |
| 2024-03-14 | Chris Senanayake | Director | Sell (S) | −1,626 | $1.60 | -$2.6K | EDGAR |
| 2024-03-08 | Michael Vander Hoek | Chief Financial Officer | Award (A) | +100,000 | — | EDGAR | |
| 2024-01-02 | Milton Brown | Director | Sell (S) | −2,921 | $0.46 | -$1.4K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
SHPH Insider Holdings
2 insiders · @ $5.04
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | HRT FINANCIAL LP | 10%+ Owner | 60,238 | $303.9K | -$323.1K | 6 | 2026-07-15 |
| 2 | Steven M Richards | Director | 1 | $5 | -$1.6K | 2 | 2025-08-13 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
SHPH Board & Officers
As of SEC filings through Jul 15, 2026Directors 5
- Anatoly Dritschilo · since Aug 29, 2022
- George Scorsis · since Feb 28, 2025
- Joseph Tung · since Feb 28, 2025
- Adam V Chambers · since Sep 8, 2025
- Angel Liriano · since Sep 12, 2025
Officers 2
- Ryan Trasolini · Co-Chief Executive Officer · since May 6, 2026
- Yuying Liang · Chief Financial Officer · since Jan 6, 2026
Changes in the last 10 years (36)
| Jul 15, 2026 | Hrt Financial LP reported in an SEC filing no longer being a 10% owner |
| Jul 13, 2026 | Hrt Financial LP first listed as a 10% owner in an SEC filing |
| Jul 9, 2026 | Hrt Financial LP reported in an SEC filing no longer being a 10% owner |
| Jun 29, 2026 | Hrt Financial LP became a 10% owner |
| May 6, 2026 | Ryan Trasolini became Co-Chief Executive Officer |
| May 1, 2026 | The company announced the departure of Oleh Nabyt from the board in an SEC filing |
| Jan 8, 2026 | The company announced the departure of Arachchige Sachin Eranga Pathigoda from the board in an SEC filing |
| Jan 6, 2026 | Yuying Liang became Chief Financial Officer |
| Nov 21, 2025 | The company announced the departure of Timothy J. Lorber as Chief Financial Officer in an SEC filing |
| Sep 12, 2025 | Arachchige Sachin Eranga Pathigoda became a director |
| Sep 12, 2025 | Angel Liriano became a director |
| Sep 8, 2025 | Adam V Chambers became a director |
| Aug 31, 2025 | The company announced the departure of Steven M Richards from the board in an SEC filing |
| Mar 11, 2025 | Chris Cooper became Interim Co-CEO |
| Feb 28, 2025 | The company announced the departure of Milton Brown from the board in an SEC filing |
| Feb 28, 2025 | The company announced the departure of Chris Senanayake from the board in an SEC filing |
| Feb 28, 2025 | The company announced the departure of Bette Jacobs from the board in an SEC filing |
| Feb 28, 2025 | Oleh Nabyt became a director |
| Feb 28, 2025 | Joseph Tung became a director |
| Feb 28, 2025 | George Scorsis became a director |
| Jun 13, 2024 | Timothy J. Lorber became Chief Financial Officer |
| Jun 13, 2024 | The company announced the departure of Michael Vander Hoek as Chief Financial Officer in an SEC filing |
| Jan 4, 2023 | William Adkins reported in an SEC filing no longer being a director |
| Oct 28, 2022 | Bette Jacobs became a director |
| Aug 29, 2022 | William Adkins became a director |
| Aug 29, 2022 | Tyvin Rich became Chief Medical Officer |
| Aug 29, 2022 | Steven M Richards became a director |
| Aug 29, 2022 | Peter Dritschilo became President and COO |
| Aug 29, 2022 | Mira Jung became Chief Scientific Officer |
| Aug 29, 2022 | Milton Brown became a director |
| Aug 29, 2022 | Michael Vander Hoek became Chief Financial Officer |
| Aug 29, 2022 | Joshua Schafer became a director |
| Aug 29, 2022 | Chris Senanayake became a director |
| Aug 29, 2022 | Anatoly Dritschilo became a director |
| Aug 29, 2022 | Anatoly Dritschilo became a 10% owner |
| Aug 29, 2022 | Anatoly Dritschilo became CEO and Chairman |
Not reported recently (5)
- Chris Cooper · Last reported as Interim Co-CEO in an SEC filing dated Apr 2, 2025
- Joshua Schafer · Last reported as a director in an SEC filing dated Feb 6, 2025
- Mira Jung · Last reported as Chief Scientific Officer in an SEC filing dated Oct 9, 2024
- Tyvin Rich · Last reported as Chief Medical Officer in an SEC filing dated Jan 3, 2023
- Peter Dritschilo · Last reported as President and COO in an SEC filing dated Dec 30, 2022
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
ETF Holders
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.